Resonance Health Ltd (ASX: RHT) has announced changes to its Board, with Dr. Martin Blake retiring as Chair and Non-Executive Director. Mr. Aaron Brinkworth will succeed Dr. Blake as Chair following the Annual General Meeting on 13 November 2025. Additionally, Mr. Andrew Harrison, the Company's CEO, has been elected as a director and will take on the role of Managing Director. Mr. Brinkworth brings extensive experience from Gilead Sciences, Inc. and other organizations, while Mr. Harrison has led significant advancements at Resonance Health since joining in 2023.

The Company's strategic decisions aim to align and strengthen governance as it enters the next phase of growth. Resonance Health is a healthcare technology and services company known for its high-quality quantitative assessments used in disease management and clinical trials. Regulatory cleared products, including AI-powered solutions, have gained recognition globally. Investors are welcome to ask questions and find further information on the Company's website. We look forward to the significant opportunities that lie ahead for Resonance Health.